HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.
Stocks · News reference
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript
On Thursday, Kyntra Bio (NASDAQ:KYNB) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — KYNTRA BIO, INC. (KYNB)
Filed: 2026-08-31 AccNo: 0001193125-26-377059 Size: 212 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan
Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million Company accelerated payment of $42.6 million upfront, bringing total payments made to date to $50
Kyntra Bio